Levonorgestrel-releasing intrauterine system for endometrial hyperplasia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2017, Pages

  Wise, Michelle R ^a   Farrant, Charlotte ^b   Coop, Catherine ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; PLACEBO;

ADVERSE OUTCOME; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 85019083596     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012658     Document Type: Article

References (30)

1. Abu Hashim H, Ghayaty E, Rakhawy ME. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomised trials. American Journal of Obstetrics & Gynecology 2015;213(4):469-78.
2. Anastasiadis PG, Skaphida PG, Koutlaki NG, Galazios GC, Tsikouras PN, Liberis VA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. European Journal of Gynaecological Oncology 2000;21(2):131-4.
3. Crosbie E, Morrison J. Editorial: The emerging epidemic of endometrial cancer: Time to take action. www.cochranelibrary.com/editorial/10.1002/14651858.ED000095 (accessed 29th July 2015). [DOI: 10.1002/14651858.CD000095]
4. Dominick S, Hickey M, Chin J, Su IH. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2015, Issue 12. [DOI: 10.1002/14651858.CD007245.pub3]
5. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency on Research on Cancer; 2017. Available from: http://globocan.iarc.fr, accessed on 2nd May 2017. Vol. GLOBOCAN 2012 v1.1.
6. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy AMD, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics & Gynecology 2010;203(6):547.e1-10.
7. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Human Reproduction 2013;28(11):2966-71. [DOI: 10.1093/humrep/det320]
8. Giede KC, Yen TW, Chibbar R, Pierson RA. Significance of concurrent endometrial cancer in women with a preoperative diagnosis of atypical endometrial hyperplasia. Journal of Obstetrics and Gynaecology Canada 2008;30(10):896-901.
9. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 1 September 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
10. Guttinger A, Critchley H O. Endometrial effects of intrauterine levonorgestrel. Contraception 2007;75(6 Suppl):S93-8. [DOI: 10.1016/j.contraception.2007.01.015]
11. Higgins JPT, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. The Cochrane Collaboration, Available from handbook.cochrane.org.
12. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56(2):403-12.
13. Kurman RJ, Hedrick-Ellenson L, Ronnett BM, editor(s) . Blaustein's Pathology of the Female Genital Tract. 6th Edition. New York: Springer, 2011.
14. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Journal of Clinical Oncology 2010;28(5):788-92. [DOI: 10.1200/JCO.2009.24.1315]
15. Landrum L, Zuna R, Walker JL. Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. In: Di Saia P, Creasman W editor(s). Clinical Gynecologic Oncology. 8th Edition. Philadelphia: Elsevier/Saunders, 2012:121-40.
16. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
17. Lethaby A, Munawar H, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD002126.pub3]
18. Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009458.pub2]
19. Morelli M, Di Cello A, Venturella R, Mocciaro R, D'Alessandro P, Zullo F. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecological Endocrinology 2013;29(2):156-9. [DOI: 10.3109/09513590.2012.730579]
20. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. Clinical guideline [CG44]. Published date: January 2007. Last updated: August 2016. www.nice.org.uk/guidance/cg44 (accessed 30th July 2015).
21. Pfizer New Zealand Ltd. Provera Medroxyprogesterone acetate data sheet October 2016. http://www.medsafe.govt.nz/profs/Datasheet/p/Proveratab.pdf (accessed 28th April 2017).
22. Gallos ID, Alazzam M, Clark TJ, Faraj R, Rosenthal AN, Smith PP, Gupta JK. Management of Endometrial Hyperplasia. Green-top Guideline No. 67. www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf (accessed 30th July 2015).
23. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
24. Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BWJ. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD008994.pub2]
25. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours. In: Sobin LH editor(s). International Histological Classification of Tumours. 2nd Edition. Berlin, Heidelberg: Springer-Verlag, 1994. [DOI: 10.1007/978-3-642-85014-1]
26. Singh S, Best C, Dunn S, Leyland N, Wolfman WL, Clinical Practice - Gynaecology Committee, et al. SOGC Clinical Practice Guideline: abnormal uterine bleeding in pre-menopausal women. Journal of Obstetrics and Gyynaecology Canada 2013;35(5 Suppl 1):S1-S28.
27. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106(4):812-9.
28. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system Is an effective treatment in selected obese women with abnormal uterine bleeding. Journal of Minimally Invasive Gynecology 2011;18(1):75-80. [DOI: 10.1016/j.jmig.2010.09.013]
29. Wise M, Jordan V, Lagas A, Showell M, Wong N, Lensen S, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. American Journal of Obstetrics & Gynaecology 2016; Vol. 214, issue 6:689.e1-e17. [DOI: 10.1016/j.ajog.2016.01.175]
30. Zaino R, Carinelli SG, Ellenson LH. Tumours of the uterine corpus: epithelial tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH editor(s). WHO Classification of Tumours of Female Reproductive Organs. 4th Edition. Lyon: WHO Press, 2014:125-6.